Inozyme Pharma Inc
INZY3.950USD
+2.530+178.17%
收盘 05/16, 16:00（美东）报价延迟15分钟
254.66M总市值
亏损市盈率 TTM
关于 Inozyme Pharma Inc 公司
Inozyme Pharma, Inc. 是一家临床阶段的罕见病生物制药公司。该公司专注于开发治疗影响血管、软组织和骨骼疾病的新型疗法。该公司还专注于开发一种新型疗法来治疗罕见遗传病，即外核苷酸焦磷酸酶/磷酸二酯酶 1 (ENPP1) 和 C6 家族中的 ATP 结合盒 (ABCC6) 缺乏症。该公司的主要候选产品 INZ-701 是一种可溶性重组基因工程融合蛋白，旨在裂解细胞外三磷酸腺苷 (ATP) 以产生血浆焦磷酸 (PPi) 和单磷酸腺苷 (AMP)，后者可加工成磷酸盐和腺苷。其 INZ-701 正在临床开发中，用于治疗 ENPP1 缺乏症、ABCC6 缺乏症和钙化防御。
公司简介
公司代码INZY
公司名称Inozyme Pharma Inc
上市日期Jul 24, 2020
成立日期2015
CEODr. Douglas A. (Doug) Treco, Ph.D.
员工数量67
证券类型Ordinary Share
年结日Jul 24
公司地址321 Summer Street
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02210
电话18573304340
网址https://www.inozyme.com/
公司代码INZY
上市日期Jul 24, 2020
成立日期2015
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Axel Bolte
Mr. Axel Bolte
Director
Director
266.70K
--
Dr. Matthew Winton, Ph.D.
Dr. Matthew Winton, Ph.D.
Chief Operations Officer
Chief Operations Officer
7.39K
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Sarah M. Bhagat, Ph.D.
Dr. Sarah M. Bhagat, Ph.D.
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Lead Independent Director
Lead Independent Director
--
--
Dr. Douglas A. (Doug) Treco, Ph.D.
Dr. Douglas A. (Doug) Treco, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Lynne Sullivan, CPA
Ms. Lynne Sullivan, CPA
Independent Director
Independent Director
--
--
Mr. Erik Harris
Mr. Erik Harris
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Axel Bolte
Mr. Axel Bolte
Director
Director
266.70K
--
Dr. Matthew Winton, Ph.D.
Dr. Matthew Winton, Ph.D.
Chief Operations Officer
Chief Operations Officer
7.39K
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Dr. Sarah M. Bhagat, Ph.D.
Dr. Sarah M. Bhagat, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
股东统计
占比
Longitude Capital Management Co., LLC
9.05%
Adage Capital Management, L.P.
7.99%
Pivotal Bioventure Partners Investment Advisor LLC
6.96%
Sofinnova Investments, Inc
6.63%
Affinity Asset Advisors LLC
5.99%
Other
63.38%
持股股东
股东统计
占比
Longitude Capital Management Co., LLC
9.05%
Adage Capital Management, L.P.
7.99%
Pivotal Bioventure Partners Investment Advisor LLC
6.96%
Sofinnova Investments, Inc
6.63%
Affinity Asset Advisors LLC
5.99%
Other
63.38%
股东类型
股东统计
占比
Hedge Fund
30.25%
Venture Capital
29.01%
Investment Advisor/Hedge Fund
12.31%
Investment Advisor
11.71%
Research Firm
0.92%
Corporation
0.69%
Private Equity
0.68%
Individual Investor
0.54%
Bank and Trust
0.10%
Other
13.80%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
216
60.54M
94.21%
-7.78M
2024Q4
214
60.27M
93.82%
-9.91M
2024Q3
191
62.40M
99.19%
-7.69M
2024Q2
189
61.61M
98.84%
-3.38M
2024Q1
182
57.68M
93.47%
-8.16M
2023Q4
168
57.62M
93.40%
-5.18M
2023Q3
173
55.08M
89.40%
+6.47M
2023Q2
167
38.83M
84.32%
-10.19M
2023Q1
159
36.61M
84.56%
-4.82M
2022Q4
151
33.67M
83.45%
-6.75M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Longitude Capital Management Co., LLC
5.84M
9.09%
--
--
Apr 22, 2024
Adage Capital Management, L.P.
5.16M
8.03%
-513.63K
-9.05%
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
4.49M
7%
--
--
Dec 31, 2024
Sofinnova Investments, Inc
4.28M
6.66%
--
--
Dec 31, 2024
Affinity Asset Advisors LLC
3.97M
6.18%
+1.15M
+40.75%
Dec 31, 2024
Rock Springs Capital Management LP
3.86M
6.01%
+59.10K
+1.55%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
3.49M
5.43%
+313.70K
+9.87%
Dec 31, 2024
The Vanguard Group, Inc.
2.63M
4.1%
+8.91K
+0.34%
Dec 31, 2024
New Enterprise Associates (NEA)
2.44M
3.79%
--
--
Dec 31, 2024
Samsara BioCapital, LLC
1.56M
2.43%
--
--
Dec 31, 2024
查看更多
持股ETF
更新时间: 5月6日 周二
更新时间: 5月6日 周二
机构名称
占比
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
iShares Russell 3000 ETF
0%
iShares Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
查看更多
Invesco Nasdaq Biotechnology ETF
占比0.01%
ProShares Ultra Nasdaq Biotechnology
占比0.01%
iShares Micro-Cap ETF
占比0.01%
iShares Russell 3000 ETF
占比0%
iShares Russell 2000 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
Fidelity Nasdaq Composite Index ETF
占比0%
Global X Russell 2000 ETF
占比0%
Global X Russell 2000 Covered Call ETF
占比0%
DFA Dimensional US Core Equity Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
